SML3605
Selexipag
≥98% (HPLC)
别名:
2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide, ACT-293987, NS-304
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H32N4O4S
化学文摘社编号:
分子量:
496.62
UNSPSC Code:
51111800
NACRES:
NA.21
MDL number:
产品名称
Selexipag, ≥98% (HPLC)
InChI key
QXWZQTURMXZVHJ-UHFFFAOYSA-N
SMILES string
CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Selexipag is a potent, highly selective and orally available nonprostanoid agonist for the PGI2 receptor (IP receptor). Selexipag is readily hydrolyzed to the active metabolite ACT-333679 (MRE-269), which is also a potent and selective agonist at IP receptors. In contrast to the prostacyclin analogs iloprost and beraprost, selexipag and metabolite ACT-333679 does not contract gastric fundus up to mM concentrations.
Potent, highly selective and orally available agonist for the PGI2 receptor (IP receptor); nonprostanoid IP receptor agonist
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug
Journal of Pharmacology and Experimental Therapeutics, 322, 1181-1188 (2007)
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery
Journal of Pharmacology and Experimental Therapeutics, 326(3), 691-699 (2008)
Keith Morrison et al.
The Journal of pharmacology and experimental therapeutics, 335(1), 249-255 (2010-07-28)
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension. Selexipag is highly selective for the human IP receptor in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持